# BioMotiv

> BioMotiv is a VC fund in Cleveland backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cleveland, United States
- Total investments: 5
- Last investment: Mar 2021
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/3217531
- Website: http://www.biomotiv.com

BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how newbreakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally.The company was founded in 2012 and is headquartered in Cleveland, Ohio.

## Contacts

5 contacts available for BioMotiv. Shizune tracks 4 team members at BioMotiv. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biomotiv?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Therapeutics | 2 | 40% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 40% |
| United Kingdom | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ronald G. Harrington | Chairman | 0 | — |
| Satish Jindal | Chief Executive Officer | 2 | https://shizune.co/investors/profile/satish-jindal |
| Ted Torphy | Chief Scientific Officer | 0 | — |
| Thomas J. Facklam | Senior Vice President | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amphista Therapeutics | Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. | $53M | Series B | Mar 17, 2021 |  |
| Aro Biotherapeutics | Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action.Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids. | $88M | Series A | Jan 05, 2021 |  |
| Amphista Therapeutics | Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. | $7.5M | Series A | Apr 07, 2020 |  |
| Aro Biotherapeutics | Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action.Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids. | $13M |  | Dec 11, 2018 |  |
| Allinaire Therapeutics | Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases. The technology is based on the discovery by scientific founders Irina Petrache, MD, and Matthias Clauss, Ph.D. of a novel therapeutic target that plays a central role in the development and progression of lungdisease. | $1.6M | Seed | Jan 27, 2017 |  |

5 of 5 investments shown.

## Co-investors
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 2 deals together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 2 deals together
- [BioCrossroads](https://shizune.co/investors/profile/biocrossroads) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does BioMotiv invest in?

BioMotiv invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BioMotiv?

Public channels for BioMotiv include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioMotiv?

The team at BioMotiv includes Ronald G. Harrington (Chairman), Satish Jindal (Chief Executive Officer) and Ted Torphy (Chief Scientific Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co